What Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas

Similar documents
Complex PCI. Your partner in complex PCI: In-stent restenosis (ISR)

Calcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

DESolve NX Trial Clinical and Imaging Results

Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?

The BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino

OCT GUIDED TREATMENT OF CALCIFIED LESIONS RICHARD SHLOFMITZ, MD CHAIRMAN OF DEPT. OF CARDIOLOGY ST. FRANCIS HOSPITAL ROSLYN, NEW YORK

Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results

LM stenting - Cypher

TLR des Stents Actifs

EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb

DISRUPT CAD. Todd J. Brinton, MD Clinical Associate Professor of Medicine Adjunct Professor of Bioengineering Stanford University

Atherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System

Pathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

OCT guided procedures in peripheral intervention

IN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014

PCI for Ostial Lesion

INSIDE INFORMATION YOU CAN T IGNORE

DES In-stent Restenosis

Efficacy of DEB in Calcification and Subintimal Angioplasty

Percutaneous Intervention of Unprotected Left Main Disease

Next Generation Drug- eluting Stent : Will It Solve the Problem?

PCI for In-Stent Restenosis. CardioVascular Research Foundation

Post PCI functional testing and imaging: case based lessons from FFR React

Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?

Goal: Optimal Stent Deployment

William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA

Clinical benefits on DES Patient s perspectives

Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες

Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD

In-stent Restenosis Diagnostic and Therapeutic Challenges. Kostis Raisakis General Hospital of Athens «G. Gennimatas»

PCI vs. CABG From BARI to Syntax, Is The Game Over?

Incidence and Treatment for LM In-Stent

Cutting/scoring balloon Cryoplasty Drug-eluting balloon Brachytherapy Debulking Restent (BMS or DES) John R. Laird, MD

Drug eluting balloons in CAD

Vessel Preparation Prior to DCB and Stenting: How to Do It.

Bifurcation Stenting: IVUS and OCT Information

ΣΥΜΠΛΟΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΔΙΧΑΣΜΩΝ

PCI for Long Coronary Lesion

Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND

Merits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁

Intravascular Imaging Insights into the Mechanism of Action of Focal Force Balloon Angioplasty

Bioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals

Prognostic Value of Gated Myocardial Perfusion SPECT

Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA

The essentials for BTK procedures: wires, balloons, what else

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty

DISCOVER Ultimaster with Optical Frequency Domain Imaging

IVUS vs FFR Debate: IVUS-Guided PCI

FFR Incorporating & Expanding it s use in Clinical Practice

FANTOM II trial: Clinical results from the Fantom Sirolimus-Eluting BRS. Norbert Frey, MD University of Kiel, Germany

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Lessons learned From The National PCI Registry

Drug Eluting Stents: Bifurcation and Left Main Approach

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

Important LM bifurcation studies update

In-Stent Restenosis. Can we kill it?

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.

Emerging Cardiac Technologies. Thomas D. Conley, MD FACC FSCAI BHHI Primary Care Symposium February 27, 2015

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Nobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

Protection of side branch is essential in treating bifurcation lesions: overview

Perspective of LM stenting with Current registry and Randomized Clinical Data

Tratamiento de la Reestenosis del Stent Farmacoactivo

Contemporary therapy of bifurcation lesions

Nicolas W Shammas, MD, MS

Endovascular Options in Critical Limb Ischemia: Below The Knee Therapies

Bioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland

INTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY. SeQuent Please NEO CLINICAL EVIDENCE AND COST / BENEFIT EFFECTIVENESS

Complex Coronary Interventions: Bifurcations. John M. Lasala MD PhD Professor of Medicine Washington University St Louis, Missouri

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators

Evolution In Interventional Cardiology. Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands

PCI with DEB only for Bifurcation Lesions

Disclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland

CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer

Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI

Surgery Grand Rounds

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

DISAPPEARING STENT: IS THE TIME APPEARED?

Αγγειοπλαστική με απλό μπαλόνι και με μπαλόνια που αποδεσμέουν φαρμακευτική ουσία.

The role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium

Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD

PCI for Chronic Total Occlusions

IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation

Que nos puede aportar el OCT intracoronario

Unprotected LM intervention

Interventional Cardiology חיים דננברג מערך הלב

Specificities for infrapopliteal stents

Lessons learnt from DES in the SFA is there any ideal concept so far?

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

Cardiovascular Systems, Inc. NASDAQ: CSII. Stifel California Bus Tour December 12, 2017

RESTENOSIS Facing up to the problem

PCI for Bifurcation Coronary Lesion

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

Davide Capodanno, MD, PhD Associate Professor, University of Catania, Italy

Christian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide

Transcription:

What Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas

Stent Era Lessons on Vessel Preparation Under expanded stent consequences Abrupt closure Subacute thrombosis Restenosis Vessel expansion Tools IVUS for Coronary Area Vessel Preparation Options PTCA Directional Atherectomy- BOAT and OARS Trials Atherectomy- Rotational and Orbital Bioresorbable Coronary stent preparation

Risk Factors for Morbidity and Mortality in PCI Multivessel CAD Lesion Eccentricity Presence of Calcium in the Lesion Female Gender Lesion Length 10 8 6 4 2 0 % of Patients with Major Complications Mutivessel CAD Single Vessel CAD Eccentric Concentric Calcium No Calcium Female Male Bresdlau CE et al. Circulation. 1985;72:1044-1052.

Stent Expansion Lessons IVUS

Stent Underexpansion Consequences: Thrombosis Minimum Cross Sectional Area by IVUS (MSA) Stent Expansion % Significant Segment Stenosis 90 80 70 60 50 40 30 20 10 0 Risks of Stent Thombosis MSA Stent Expansion Significant Stenosis Thrombosis No Thrombosis Kenichi Fuji et al. JACC April 2005;Volume 45, Issue 7. pp 995-998

Stent Underexpansion Consequences: Restenosis IVUS for assessment of ISR MSA of < 5mm 2 associated with absence of restenosis 80 70 60 50 40 30 20 10 0 Risks of Stent Restenosis MSA >5 MSA <4 MSA,3 Restenosis No Restenosis Kenichi Fuji et al.(mintz/leon) Circulation:2004;109:1085-1088

Vessel Preparation Options Rotational and Laser Atherectomy Pre Stent Rotational Atherectomy- vessel prep Post Stent- Underexpanded stent treatment- Stentblation Post Stent Underexpanded- Contrast assisted Laser Ablation Lori Vales et al. Int J. Angio. 2013 Mar; 22(1): 63 68 Ashikaga, et al. Cath Cardiov Interv 2015 Nov;86(5):946-9.

Vessel Preparation Options Directional Atherectomy Developed in 1984 1020 Procedures studied Goal <20% residual stenosis Bigger is Better 100 80 60 40 20 0 CAVEAT Trial Results Crossover Success Immediate Gain MI Composite Restenosis Atherectomy Balloon Topol et al. NEJM 1993; 329;221-227 CAVEAT Trial Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with CAD

Lesion Calcification Impact on DES Implantation in Real-World Patients Severe calcium makes stent expansion difficult and can contribute to higher MACE and mortality rates in complex PCI patients Optimal stent expansion may decrease rates 16 14 12 10 8 6 4 2 May reduce length of stay and complications 0 % Restenosis TLR Stent Thrombosis MACE Calcified Non-Calcified Kawaguchi R, Tsurugaya H, Hoshizaki H, et al. Impact of lesion calcification on clinical and angiographic outcome after sirolimus-eluting stent implantation in real-world patients. Cardiovasc Revasc Med. 2008;9:2-8.

ORBIT II Clinical Data 443 Patients Severely Calcified Cor. Lesions Primary Safety Endpoint: Freedom from 30d MACE 89.6% with performance goal of 82% Primary Efficacy Endpoint (<50% residual and w/o MACE in hospital) 88.9% compared to performance goal of 82% Stent Delivery Success 97.7% 1 yr TLR of 4.7% Chambers JW et. Al. JACC Cardiovasc Interv.2014 May; 7(5);510-8

Compliance 360º Study Design 10 0 Prospective, multi-center Randomized (1:1) Calcified ATK lesions Mean Max Balloon Pressure 4.0+1.3 OAS *p < 0.0001 9.1+3.5 PTA 100 0 % Lesions Requiring Bail-Out 5,3 77.8 OAS PTA *p < 0.0001 OAS + POBA N=25 N=50 POBA N=25 The Lowest Balloon Inflation Pressure Used to Achieve Desired Outcome = Compliance Change

ABSORB Biodegradable Stents vs. DES with OCT Guidance Figure 1. Qualitative and Quantitative Assessment of OCT Characteristics A. An example of incomplete strut apposition (ISA). There are 4 malapposed struts between 10 and 12 o'clock position in A1 B. Tissue prolapse. In the presence of tissue prolapse, defined as tissue protruding between the struts, the prolapse area was measured as the difference between the stent and lumen area (highlighted in green in B2). C. An example of edge dissection (arrow) distal to the BVS. D. A BVS strut fracture. Mettesini A. et al. JACC: CV interv. Volume 7, Issue 7, July 2014. P. 741-50

Three Year Outcomes with Absorb Bioresorbable Scaffold (Individual-Patient-Data Meta-Analysis from the ABSORB trial) 14 12 10 8 6 4 2 0 Target Lesion Failure Target Vessel MI Ischemia driven TLR Cardiac Mortality BVS Everolimus DES Ali ZA, Stone G. et. al. Circulation 2017;136:

Conclusions Coronary Vessel Preparation may have implications on acute procedural and post procedural outcomes Coronary Calcification portends worse outcomes Poor Stent expansion is directly related to increased rates of thrombosis and restenosis Unclear correlation between coronary vessel preparation and peripheral arterial vessel preparation Proponents of Vessel Prep site DEFINITIVE AR and look towards REALITY and DEB trials

November 5-8, 2018 at Wynn Las Vegas, Nevada, USA Attend the conference live from your computer!

What Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas